Form 4: Soleno Therapeutics Merger Completes, Executive Stock Options Canceled

Soleno Therapeutics, Inc. announced the completion of its merger with Neocrine Biosciences, Inc., resulting in the cancellation of executive stock options and restricted stock units for cash.

Summary

• The filing reports on changes in beneficial ownership for Jennifer Fulk, Chief Financial Officer of Soleno Therapeutics Inc.
• The transactions are related to the completion of a merger between Soleno Therapeutics, Inc. and Neocrine Biosciences, Inc. (via Merger Sub) on May 18, 2026.
• As a result of the merger, Jennifer Fulk's previously reported restricted stock units (RSUs) were cancelled and converted into the right to receive $53.00 in cash per unit.
• Additionally, her employee stock option, with an exercise price of $39.06, was cancelled in exchange for a cash payment calculated based on the merger consideration and exercise price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it reports on the completion of a merger and the subsequent conversion of executive equity into cash, which is a standard outcome of such transactions.

Positives

• The merger completion provides a cash payout of $53.00 per share for vested and unvested RSUs.
• Executive stock options were also converted into a cash payment, providing liquidity to the holder.

Negatives

• All previously held restricted stock units (RSUs) were cancelled as part of the merger.
• Employee stock options were cancelled, eliminating the potential for future upside from stock appreciation.

Future Outlook

The filing does not contain forward-looking statements or guidance; it reports on a completed merger event.

Industry Context

StockSavvy.ai notes that the completion of mergers and acquisitions is a common strategic event in the biotechnology and pharmaceutical sectors, often leading to the conversion of equity awards into cash for executives.

Stakeholder Impact

• Shareholders of Soleno Therapeutics, Inc. received $53.00 in cash for each vested and unvested RSU.
• Executives holding stock options received a cash payout based on the difference between the merger consideration and their exercise price.

Next Steps

• The company will continue as a wholly owned subsidiary of Parent (Neocrine Biosciences, Inc.) following the merger.

Key Dates

Keywords

Soleno Therapeutics, Neocrine Biosciences, Merger, Form 4, SEC Filing, Executive Compensation, Stock Options, RSUs, Beneficial Ownership